Erik Penser Bank has initiated coverage of Hansa Biopharma with a buy recommendation

Read initiation report

Capital Markets Day was held on October 29, 2020, highlighting commercialization of Idefirix® and opportunities beyond kidney transplantation

See presentation & webcast

Annual General Meeting was held on May 12th 2021. All proposals were approved

Read bulletin

Company collected consensus available from 10 banks and research institutions

Read more

Recent webcasts from Redeye and Nordnet biotech events available on our web

See presentations

CEO Søren Tulstrup has increased his holdings in Hansa Biopharma

Read more

Danske Bank has initiated coverage with a buy recommendation

Full analyst coverage

Updated financial calendar and investor events

See calendar

ABG Sundal Collier hosted a call KOL expert call Dr. Bengt von Zur-Mühlen on 2021-03-24

View webcast

Hansa Biopharma in brief

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients.

The Company has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer.

Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Commercialize Idefirix® in first markets and indications
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More

Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcomming Events

Milestones and near-term news flow

Near Term News Near Term News

For any investor related inquiries, please contact